Abstract Background Use of Botulinum toxin-A (BoNT-A) for treatment of upper limb
spasticity in children with cerebral palsy has become routine clinical practice in many …

Botulinum toxin type A (BoNT-A) therapy has gained wide acceptance in the management of
spasticity in cerebral palsy (CP). Clinical experience from numerous case reports and series …

Poststroke hemiparesis, together with abnormal muscle tone, is a major cause of morbidity
and disability. Although most hemiparetic patients are able to reach different ambulatory …

Over the past 5 years a number of studies of the use of Botulinum toxin A in the management
of cerebral palsy have been conducted. Overall 105 children, with a mean age of 6 years …

✓ Hypertonicity is a leading cause of disability for children with cerebral palsy (CP).
Botulinum toxin A (BTA) chemically denervates muscle tissue and is commonly used in the …

Aim The aim of this study was to determine the effects of repeat botulinum toxin A (Bo NT‐A)
injections in children with spastic cerebral palsy (CP) on the basis of a best evidence …

Adductor spasticity in children with cerebral palsy (CP) impairs motor function and
development. In a placebo-controlled, double-blind, randomized multicentre study, we …

A prospective cohort study with annual follow-up was conducted on 172 children with
spastic type cerebral palsy receiving botulinum toxin type A (BTX) injections for spasticity …

Question What is the role of intramuscular botulinum toxin injections in the management of
spasticity and related morbidity in children with cerebral palsy? Answer When botulinum …

Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic
cerebral palsy, but its added value preceding comprehensive rehabilitation for motor …